Sai Parenterals Limited – Investor Presentation Summary

Key Operational Highlights

  • Consolidated revenue from operations reached ₹196.1 crore in Q2FY27, up 9% sequentially from ₹179.9 crore in Q1FY27
  • H1FY27 revenue stood at ₹376.0 crore, representing 50% of the FY27 target of ₹750 crore
  • Gross margin improved to 47.5% in Q2FY27 from 40.9% in Q1FY27 due to tighter inventory management and new ERP system implementation
  • Australia accounted for 76% of export revenue (down from 83% in Q1FY27)
  • Philippines portfolio expanded with 11 molecules and 22 SKUs added during Q2FY27, led by cardiovascular therapies
  • Group-wide capacity utilization varies by unit: Unit II (sterile penicillin) at 97%, Unit III (oral solids) at 87% in H1FY26, Unit IV at 39%, Revat Unit at 65%

Segment-wise Performance

  • CDMO Exports: 63% of FY26 net revenue; 355.6% CAGR over FY23–FY26 on long-term contracts
  • Branded Generics: 37% of FY26 net revenue; 15.6% CAGR over FY23–FY26 on consistent launches
  • Noumed Platform: Contributed 76% of export revenue in Q2FY27; contracted Australian OTC book at AUD 232 million (~₹1,506 crore)

Financial Highlights

Q2FY27 Performance:

  • Revenue: ₹196.1 crore (+257.4% YoY, +9.0% QoQ)
  • EBITDA: ₹41.4 crore (+224.4% YoY, +67.4% QoQ)
  • EBITDA Margin: 21.1% (vs 23.3% YoY, 13.7% Q1FY27)
  • PAT: ₹10.5 crore (+45.9% YoY, +32.7% QoQ)
  • PAT Margin: 5.4% (vs 13.1% YoY, 4.4% Q1FY27)

H1FY27 Performance:

  • Revenue: ₹376.0 crore (+321.0% YoY)
  • EBITDA: ₹66.1 crore (+256.3% YoY)
  • EBITDA Margin: 17.6% (vs 20.8% YoY)
  • PAT: ₹18.4 crore (+137.4% YoY)
  • PAT Margin: 4.9% (vs 8.7% YoY)

Drivers of financial performance: Higher revenue growth from full consolidation of Noumed, improved gross margins from better inventory management, and operational efficiencies

Geographical Revenue Split

  • Domestic vs Export Revenue: Not explicitly split for current period
  • Export markets: Australia (76% of export revenue), Philippines, Middle East, Latin America
  • Regional breakdown: Australia remains dominant export market; Philippines showing growth with new molecule additions

Balance Sheet Snapshot

As of H1FY27:

  • Total Assets: ₹1,319.8 crore
  • Property, plant and equipment: ₹82.6 crore
  • Right of use Assets: ₹125.5 crore
  • Capital work-in-progress: ₹269.3 crore
  • Inventories: ₹182.2 crore
  • Cash and cash equivalents: ₹129.3 crore
  • Trade receivables: ₹254.5 crore
  • Shareholders' funds: ₹508.1 crore
  • Borrowings: ₹356.6 crore (₹81.2 crore non-current, ₹275.4 crore current)

Capex & Cash Flow Health

  • Capital Expenditure: Total planned capex programme of ₹571 crore at group level
  • Free Cash Flow: Not explicitly stated
  • Operating Cash Flow: Net cash from operating activities was -₹205.5 crore in H1FY27
  • Net Debt Movement: Cash decreased by ₹287.6 crore in H1FY27 to ₹129.3 crore
  • Investment Rationale: Focus on capacity expansion (new injectable facility, Unit III expansion), technology upgrades, and regulated market access

Strategic & R&D Initiatives

  • Acquisition of Saicriti Pharma: 60% stake acquired for ₹83.83 crore; new injectable facility with 154.66 mn units capacity targeting July 2027 completion
  • Acquisition of Sai Prathyak Laboratories: 60% stake acquired for ₹15 crore; operating R&D centre with 28 research scientists and 174 molecules/285 SKUs portfolio
  • Adelaide Facility: AUD 53 million (₹311 crore) project in Australia; operations begin January 2027, commercial supply from April 2027
  • Unit III Expansion: Capacity increased from 85.5 to 155 million units per month; completed in Q2FY27
  • R&D Capabilities: 76 dossiers under development targeted for FY28; 98 dossiers developed in-house to date with 45 commercialized

Industry Trends & Business Environment

  • Global injectable market represents ~29% of global pharmaceutical market by value, growing at 6.5% CAGR
  • Global CDMO market valued at USD 297 billion in 2025, forecast to exceed USD 609 billion by 2033 (9.4% CAGR)
  • Global generics market represents 50.8% of total pharmaceutical market, growing at 6.5% CAGR to $1,334 billion by 2033
  • Australia & New Zealand CDMO markets expected to grow at ~11.2% CAGR till 2033
  • Indian market dominated by generics (~90% of consumption by value) with expanding government healthcare infrastructure

Management Commentary & Growth Outlook

Strategic Outlook: "Q2FY27 is the quarter in which our transformation began to show in our profitability. With H1 ahead of plan and the second half seasonally our stronger period, we are well placed for FY27. FY27 remains a year of building, and FY28 is when that build should begin to show in our performance." - Anil Kumar Karusala, Chairman and Managing Director

FY Guidance:

  • Revenue target: ₹750 crore for FY27
  • EBITDA margin: ~17% for FY27 (H1FY27 achieved 17.6%)
  • Key drivers: Existing long-term supply contracts, ramp-up in CDMO exports, full-year contribution from Noumed

Risks and Opportunities: Focus on completing capex programme on time, integrating acquisitions, and realizing synergies between Sai and Noumed

Additional Updates

  • Variation in IPO proceeds utilization: ₹83.8 crore reallocated from Unit I/II upgrade to Saicriti acquisition; ₹15 crore reallocated from new R&D centre to Prathyak acquisition
  • Noumed renewed AUD 30 million OTC supply agreement in August 2026, following 7.5-year AUD 202 million renewal in July 2026
  • Manufacturing rights acquired to Sai Prathyak's 174-molecule, 285-SKU portfolio across critical care and oncology
  • Accreditation timeline: New injectable facility targeting EU-GMP, USFDA, WHO-GMP, PIC/S standards within 12 months of July 2027 completion